GlassScriptPhysician profile
Jerusha N Muniu
NPI 1043830748
$3,328.39
in general payments reported to CMS, 2019-2025
22 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $775 · 2022: $771 · 2023: $152 · 2024: $231 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,782.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $436.80 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $404.97 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $227.69 | 2024-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $216.45 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $207.54 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $207.07 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $193.91 | 2021-2025 | Trintellix |
| Alkermes, INC. | $187.07 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $166.35 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $165.68 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $149.19 | 2021-2025 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $148.89 | 2021-2025 | Fanapt |
| Tris Pharma INC | $147.20 | 2021-2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $113.88 | 2021-2022 | |
| Lundbeck LLC | $98.96 | 2022-2025 | Brintellix, Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $78.87 | 2021-2025 | Spravato |
| Eisai INC. | $51.45 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $43.62 | 2022 | |
| Validus Pharmaceuticals LLC | $36.73 | 2022 | |
| Noven Therapeutics, LLC | $16.70 | 2023 | Xelstrym, Secuado |
| Collegium Pharmaceutical, INC. | $15.39 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $13.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerusha Muniu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.